NovaBridge Biosciences (NBP) Other Accumulated Expenses (2022 - 2025)

NovaBridge Biosciences (NBP) has reported Other Accumulated Expenses for 4 consecutive years, with $9.2 million the latest figure, recorded in Q4 2025.

• Quarterly Other Accumulated Expenses rose 8560.38% year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (up 8560.38% YoY) and the FY2025 annual result came in at $9.2 million, up 8560.38% from the prior year.
• Other Accumulated Expenses rose to $9.2 million in Q4 2025 per NBP's latest filing, from $2.3 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for NBP reached as high as $9.2 million in Q4 2025 and fell as low as $106000.0 in Q4 2024.
• A 4-year average of $4.6 million and a median of $3.6 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 97.82% — and 2025, when it soared 8560.38%.
• Year by year, Other Accumulated Expenses stood at $9.1 million in 2022, then sank by 46.54% to $4.9 million in 2023, then slumped by 97.82% to $106000.0 in 2024, then surged by 8560.38% to $9.2 million in 2025.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $9.2 million, $2.3 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.